LoadingLoadingLoadingThe quick read
Latest quote·Oct 16
Net buying: insiders sold $0 and bought $3K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet buying: insiders sold $0 and bought $3K of AZN stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. The largest was Sharma, Mani (See Remarks), who bought $3K. The latest filing was on Sep 11, 2026.
None. No member of Congress disclosed a AZN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders are trading both ways.
Buys/Adds (1)
D.E. Shaw
$202.6M
added
Sells/Trims (2)
Millennium
$146.6M
trimmed
Alger
$125.1M
trimmed
No tracked top-trader positions in AZN right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 27, 2026
Period ending
Jun 30, 2026
Earnings per share
$2.50 expected
Revenue
No reported revenue on record
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 27, 2026 | $2.18 / $2.50Alpha Vantage | -12.80% miss | Unavailable | Unavailable |
| Mar 31, 2026 | Apr 29, 2026 | $1.29 / $1.27Alpha Vantage | +1.57% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | $1.19 / $1.13Alpha Vantage | +5.31% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 29, 2025 | $0.79 / $0.88Alpha Vantage | -10.23% miss | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 29, 2025 | $1.25 / $1.12Alpha Vantage | +11.61% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 6, 2025 | $1.05 / $1.04Alpha Vantage | +0.96% in line | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 12, 2024 | $1.04 / $1.03Alpha Vantage | +0.97% in line | Unavailable | Unavailable |
| Jun 30, 2024 | Jul 25, 2024 | $0.99 / $0.99Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 18, 2026
EPS expected
$1.15 to $1.15
Revenue expected
10 analysts
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $15.19B | $15.50B | $15.29B | $15.38B |
| Cost of what it sold | $2.80B | $3.12B | $2.68B | $2.52B |
| Gross profit | $12.39B | $12.38B | $12.61B | $12.86B |
| What it spent | ||||
| Research and development | $3.66B | $3.86B | $3.49B | $4.05B |
| Sales and admin | $5.08B | $5.49B | $4.92B | $5.65B |
| Total operating expenses | $8.81B | $9.41B | $8.36B | $9.70B |
| What was left | ||||
| Operating profit | $3.58B | $2.98B | $4.25B | $3.16B |
| Interest on debt | $434.0M | $472.0M | $393.0M | $435.0M |
| Profit before tax | $3.24B | $2.63B | $3.91B | $2.80B |
| Tax | $709.0M | $300.0M | $833.0M | $291.0M |
| Net profit | $2.53B | $2.33B | $3.08B | $2.51B |
| EBITDA | $5.23B | $4.63B | $5.67B | $5.16B |
This stock's price action is mixed.
Trend
Mixed
55 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
AstraZeneca PLC Draws Bullish Targets As Oncology Deals Mount
BullishOct 14AstraZeneca PLC Stock Draws Upgrades As Oncology Deals Accelerate
BullishOct 14AstraZeneca PLC Stock (AZN) Moved Up by 3.81% on Oct 14: A Full Analysis
BullishOct 14AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
Leans bullishOct 12AstraZeneca pins bone disease drug’s Phase III failure on high placebo response
Leans bearishOct 12AstraZeneca completes Summit investment and AstraZeneca stock trades at EUR 142.63
NeutralOct 12Weekly Recap: U.S. $50B expansion and Summit stake funding ivonescimab
BullishOct 12Why Are AstraZeneca (LSE:AZN) Shares Edging Lower After The Summit Therapeutics Investment Today?
NeutralOct 9